- The European Commission grants conditional approval of Shire plc's (NASDAQ:SHPG) Natpar (rhPTH[1-84]) for the adjunctive treatment of adults with chronic hypoparathyroidism that cannot be adequately controlled with standard therapy alone.
- Hypoparathyroidism, an Orphan Disease in the EU, occurs when inadequate levels of PTH are secreted by the parathyroid glands. It is characterized by low blood calcium (hypocalcemia) and high blood phosphate (hyperphosphatemia).
- Natpar, marketed in the U.S. as Natpara, is a recombinant human protein with the full-length 84-amino acid sequence of endogenous parathyroid hormone (PTH).
- Shares are off a fraction premarket on light volume.
- Previously: European advisory committee backs conditional approval of Shire's Natpar for hypoparathyroidism; shares off 1% premarket (Feb. 24)
- Now read: Shire: A Core Buy In Biotech With Deep Late-Stage Pipeline And Continued Growth Prospects
Original article